Brand Name
Evkeeza
Generic Name
Evinacumab
View Brand Information FDA approval date: February 11, 2021
Classification: Angiopoietin-like 3 Inhibitor
Form: Injection
What is Evkeeza (Evinacumab)?
EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia . EVKEEZA is an angiopoietin-like 3 inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia . Limitations of Use: The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia . The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined. Limitations of Use: The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia . The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease
Summary: This study is researching experimental drugs called ALN-ANG3 and evinacumab (called study drugs). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in t...